Tarapeutics Science Inc. has divulged tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, fibrosis, immunological, eye and cardiovascular disorders.